GSK and Ionis Report Positive Late-Stage Trial Results for Chronic Hepatitis B Drug
GlaxoSmithKline (GSK) announced that its antisense oligonucleotide bepirovirsen, developed in collaboration with Ionis Pharma (IONS), met primary endpoints in two late-stage trials for chronic hepatitis B. The results could position the drug as a potential treatment option for this persistent viral infection.
